|
| Press Releases |
|
 |
|
| Monday, July 2, 2018 |
|
|
Eisai to Give Oral Presentation on Results of Phase III Head-to-Head Clinical Study of Lemborexant in Insomnia Disorder |
| The symposium will report on the latest data on lemborexant from non-clinical research and clinical studies relating to insomnia, including the results of SUNRISE 1. more info >> |
|
| Friday, June 22, 2018 |
|
|
Eisai Selected for Membership in MSCI Japan Empowering Women Index (WIN) |
| Eisai Co., Ltd. announced today that it has been selected for the first time for membership in the MSCI Japan Empowering Women Index (WIN), an index developed for environmental, social and governance (ESG) investment. more info >> |
|
| Thursday, June 21, 2018 |
|
|
AbbVie and Eisai Announce the Launch of HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL |
| AbbVie GK and Eisai Co., Ltd. announced that HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL, a new pediatric formulation of HUMIRA, a fully human anti-TNF-alpha monoclonal antibody formulation, has been launched today after being listed in the National Health Insurance reimbursement price list on June 15. more info >> |
|
| Thursday, June 14, 2018 |
|
|
Eisai: Industry-Academia-Government Joint Development Agreement Concerning Nucleic Acid Drug Discovery Research |
| Eisai Co., Ltd. announced today that its research subsidiary KAN Research Institute, Inc. has entered into an industry-academia-government joint research agreement with six joint research organizations concerning the "nucleic drug discovery research using novel nucleic acid synthesis and delivery technologies" research project represented by KAN. more info >> |
|
| Wednesday, June 13, 2018 |
|
|
Eisai to Establish New Research Facility "Eisai Center for Genetics Guided Dementia Discovery" in Cambridge, Massachusetts, USA |
| Eisai Co., Ltd. has announced that it has decided to establish the Eisai Center for Genetics Guided Dementia Discovery (G2D2), a new exploratory research facility focused on immuno-dementia based on human genetics, aimed at innovative drug discovery in the field of dementia, in Cambridge, Massachusetts, the United States. more info >> |
|
| Monday, June 11, 2018 |
|
|
AbbVie and Eisai Announce the Launch of HUMIRA Pen, an Auto-Injector Formulation for Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA |
| The newly launched pen-type auto-injector devices were developed to simplify the operation and reduce the burden on patients when performing self-injection. more info >> |
|
| Wednesday, June 6, 2018 |
|
|
Eisai: Positive New Data on Investigational Lemborexant Presented at 32nd Annual SLEEP Meeting |
| Eisai Co., Ltd. and Purdue Pharma L.P. presented the results of two key Phase I clinical studies (Study 108 and Study 106) of their investigational sleep/wake regulation agent lemborexant at the 32nd Annual Meeting of the Associated Professional Sleep Societies (SLEEP 2018), from June 2 to 6 in Baltimore, Maryland, the United States. more info >> |
|
| Tuesday, June 5, 2018 |
|
|
Eisai: PhaseII Clinical Study of Elenbecestat Demonstrate Safety and Tolerability in MCI and Mild to Moderate Alzheimer's Disease at 18-Months |
| Eisai Co., Ltd. and Biogen Inc. announced today that elenbecestat was generally safe and well tolerated in a Phase II clinical study (Study 202) of the oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) conducted in the United States, and the results demonstrated a statistically significant difference in amyloid beta (AB) levels in the brain measured by amyloid-PET (positron emission tomography). more info >> |
|
| Monday, June 4, 2018 |
|
|
Eisai and Merck Announce Data at 2018 ASCO Annual Meeting |
| The data are included in presentations at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 1-5. LENVIMA and KEYTRUDA are not approved for use in combination in any cancer types today. more info >> |
|
| Thursday, May 31, 2018 |
|
|
U.S. FDA Designates for Priority Review of Eisai's Supplemental New Drug Application for Antiepileptic Drug Fycoma |
| Eisai Co., Ltd. has announced the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Eisai's antiepileptic drug (AED) Fycompa (perampanel). more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Exito Media Concepts Announces the 30th Edition of the Cyber Security Summit Philippines 2026 
Mar 16, 2026 08:26 HKT/SGT
|
|
|
AdsDrama Launches Short-Drama Marketing Ecosystem Launch in the Dominican Republic, Paving the Way for Digital Content Innovation
Mar 14, 2026 05:00 HKT/SGT
|
|
|
General MRO Aerospace Achieves CAAC Certification, Expanding Global Maintenance Capabilities
Mar 13, 2026 22:20 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG) : New Drug for Renal Anaemia Desidustat Tablets Approved in China
Mar 13, 2026 22:00 HKT/SGT
|
|
|
CITIC Resources Deepens Dual-Engine Strategy of 'Investment + Trading', Continues to Promote High-Quality Development
Mar 13, 2026 21:01 HKT/SGT
|
|
|
uSMART HK Expands to 12 Physical Service Centres in One Year, Accelerating "Online x Offline" O2O Community Finance Strategy
Mar 13, 2026 17:34 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream (Lumirix(R)) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo
Mar 13, 2026 17:00 HKT/SGT
|
|
|
Mitsubishi Shipbuilding Completes Handover of WAKASHIO MARU Training Ship for National Institute of Technology, Toyama College
Mar 13, 2026 16:01 JST
|
|
|
Mitsubishi Heavy Industries to Introduce 10MW-Class Centrifugal Chiller for Next-Generation AI Data Centers in North America
Mar 13, 2026 14:10 JST
|
|
|
Revenue Triples in Four Years! Qunabox Group Reports RMB290 Million in Net Profit in 2025
Mar 13, 2026 12:27 HKT/SGT
|
|
|
Spritzer Sparkling's 'Serikan Raya, Sparkling-kan Suasana' Festive Fusion Message Promotes Togetherness and Tradition with a Light, Modern Twist
Mar 13, 2026 12:45 JST
|
|
|
Guoquan Achieves Simultaneous Growth in Scale and Profitability, Core Operating Profit Increases by 48.2% in 2025
Mar 13, 2026 10:01 HKT/SGT
|
|
|
Founders Metals Upgrades Lower Antino to Advanced Target; Hits 65.9 m of 1.16 g/t Gold
Mar 13, 2026 04:29 HKT/SGT
|
|
|
Hitachi to deliver the world's first 550 kV gas-insulated switchgear in which the entire equipment is SF(6)-free to Chubu Electric Power Grid
Mar 12, 2026 19:40 JST
|
|
|
OrbusNeich Achieves Record-breaking Revenue, Sales Volume and Gross Profit in FY2025, Net Profit Rises to US$42 million, Final Dividend Increases by 20% to HK12 Cents per Share
Mar 12, 2026 18:07 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
